Navigation Links
Certain Cholesterol Drugs Show Their Limits
Date:11/5/2007

Studies reveal that some of these heart medications aren't perfect

MONDAY, Nov. 5 (HealthDay News) -- New research is starting to show that certain cholesterol drugs have their limits and flaws.

One case in point is a study presented Monday at the American Heart Association annual meeting in Orlando, Fla. European researchers found that the statin Crestor did not reduce deaths in older patients with systolic heart failure. The drug did, however, reduce hospitalizations from cardiovascular causes. The report, which was released early to coincide with the presentation, will be published in the Nov. 29 issue of the New England Journal of Medicine.

Systolic heart failure occurs when the heart doesn't contract with enough force to push enough blood through the body. Generally, patients with systolic heart failure have not been included in statin trials because they are considered too high risk.

In this trial, more than 5,000 older patients (mean age 73) with New York Heart Association class II, III or IV ischemic systolic heart failure were randomly assigned to receive 10 milligrams of Crestor or a placebo each day.

After a median follow-up of almost three years, "there was no effect whatsoever on [cardiovascular] mortality, while there was a reduction in nonfatal [myocardial infarction] and nonfatal stroke," said Dr. Ake Hjalmarson, of the Wallenberg Laboratory for Cardiovascular Research at Sahlgrenska University Hospital in Goteberg, Sweden.

Patients taking Crestor also had 45 percent lower levels of LDL, or "bad" cholesterol, and 37.1 percent lower levels of C-reactive protein, a marker of inflammation.

"The statins did what statins are supposed to do. It's surprising that that did not translate into mortality," said Dr. Robert Bonow, immediate past president of the American Heart Association and chief of the division of cardiology at Northwestern Memorial Hospital in Chicago. "But in younger people, you may get different results."

"There are a lot of other things going on that just secondary prevention wasn't enough," Bonow said. "It doesn't mean we shouldn't be giving statins."

A second paper was the final analysis of a trial of the failed cholesterol drug torcetrapib. Pfizer Inc. pulled the drug, a CETP inhibitor, from development last December because there was an increased risk of death and other adverse outcomes, including elevated blood pressure. This study, which was released early to coincide with the meeting presentation, will be published in the Nov. 22 issue of the New England Journal of Medicine.

The adverse effects were a mystery to investigators, as the drug had succeeded in raising HDL, or "good" cholesterol levels, while lowering LDL levels.

As it turns out, the drug had unexpected side effects that may explain the paradox, according to the Australian researchers who conducted this latest analysis.

"The researchers are pointing out other things that torcetrapib did in addition to raising HDL, which is what you're trying to do," Bonow explained. "The drug also lowered LDL, but it did other things they were not anticipating."

One of these unintended consequences was to raise aldosterone levels, a hormone that helps keep a balance between sodium and potassium levels. "Aldosterone is a byproduct of angiotensin [a chemical that causes vessels to constrict], which is presumably why blood pressure was elevated," Bonow said.

"This trial leads the way open for further exploration. It neither validates nor invalidates the hypothesis that inhibition of CETP is a beneficial effect, but it will remain a hypothesis unless and until it is tested with CETP inhibitors that do not share the off-target pharmacology of torcetrapib," said study author Dr. Philip Barter, a professor at The Heart Research Institute in Sydney. "I personally look forward to more research. This drug had the potential to save hundreds of thousands of lives. I hope that the clinical benefit of this class of drug will be realized, but that is for the future."

Two other studies being presented at the meeting took a closer look at torcetrapib.

One, from the Cleveland Clinic, found that the increase in HDL cholesterol from torcetrapib did have an effect on plaque progression, as shown by intravascular ultrasound. "The target effect to raise HDL is probably beneficial because plaque didn't grow as much," Bonow said.

The second study found that the increase in blood pressure among patients taking torcetrapib was related to increased aldosterone.

The good news is that, because the negative effects of torcetrapib were "off target," the idea of targeting HDL is still sound.

"The concept is still a good concept, and other drugs will come down the pike," Bonow said.

More information

The American Heart Association has more information on cholesterol.



SOURCES: Robert Bonow, M.D., immediate past president, American Heart Association, Goldberg Distinguished professor, Northwestern University Feinberg School of Medicine, and chief, division of cardiology, Northwestern Memorial Hospital, Chicago; Philip Barter, M.D., Ph.D. The Heart Research Institute, Sydney, Australia; Ake Hjalmarson, M.D., Wallenberg Laboratory for Cardiovascular Research at Sahlgrenska University Hospital, Goteberg, Sweden; Nov. 22, 2007, New England Journal of Medicine; Nov. 29, 2007, New England Journal of Medicine; Nov. 5, 2007, presentations, American Heart Association annual meeting, Orlando, Fla.


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Use of certain lipid measures not more effective in predicting coronary heart disease
2. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
3. MU researchers studying model to learn why certain cancers become resistant to drugs
4. New All-Natural Dietary Supplement Made from Muscadine Grape Skins Helps Inhibit Growth of Certain Cancers
5. Effectiveness of most PTSD therapies is uncertain
6. Value of Most Post-Traumatic Stress Treatments Uncertain
7. Certain Seizure Patients Need Emergency CT Scan
8. Ipsen and Debiopharm Extend Their Agreement for the Exclusive Commercialization of Decapeptyl(R) (triptorelin pamoate) in Europe and Certain Other Territories
9. New review suggests caution on drugs to raise good cholesterol
10. Ability to cope with stress can increase good cholesterol in older white men, study finds
11. Handling Stress Properly Increases Good Cholesterol
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Certain Cholesterol Drugs Show Their Limits
(Date:6/27/2016)... ... 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to Best Buy ... in the United States and Canada wear eyeglasses. Once considered to be a purely ... make a fashion statement. Even celebrities use glasses as a way of creating an ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... On June ... sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, ... of the city’s history as home to some of the world’s leading providers of ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet ... product that was developed to enhance the health of felines. The formula is all-natural ... two main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews ...
(Date:6/26/2016)... ... June 26, 2016 , ... ... they have been diagnosed with endometriosis. These women need a treatment plan to ... a comprehensive approach that can help for preservation of fertility and ultimately achieving ...
(Date:6/25/2016)... ... 25, 2016 , ... Austin residents seeking Mohs surgery services, can now turn ... to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization ... selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... Forecast to 2022" report to their offering. ... the patients with kidney failure, it replaces the function of ... patient,s blood and thus the treatment helps to keep the ... balance. Increasing number of ESRD patients & ...
(Date:6/23/2016)... 2016 Research and Markets has ... by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), ... Parenteral) - Global Forecast to 2021" report to ... The global pharmaceutical excipients market is projected to reach ... 6.1% in the forecast period 2016 to 2021. ...
Breaking Medicine Technology: